Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Marseille le Cedex, France Clinical Trials

A listing of Marseille le Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Management of Paroxystic Atrial Fibrillation in French Intensive Care Units

Atrial fibrillation (AF) is a common arrhythmia in the ICU and is associated with significant morbidity. However, curative treatment remains unclearly established. In fact, there are no specific recommendations for new onset atrial fibrillation in ICU and only few studies have assessed this topic. The PAF-ICU trial is an observational, ...

Phase N/A

0.0 miles

Learn More »

Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma

The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs). The working hypothesis is that 3D brain organoids can develop glioma-like structures and recapitulate phenotypic traits of gliomas when generated from hiPSCs expressing genetic mutants ...

Phase N/A

0.0 miles

Learn More »

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

The primary objective of the study is to collect long-term safety information on anetumab ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The secondary objective is to further investigate the efficacy of the drug.

Phase

0.0 miles

Learn More »

A Study of Imlifidase in Patients With Guillain-Barr Syndrome

This is an open-label, single arm, multi-centre, phase II study of imlifidase in combination with standard care IVIg in patients with GBS. The study will recruit up to 30 patients who are eligible for IVIg treatment based on current practice (i.e. GBS disability score >3 and within 10 days of ...

Phase

0.0 miles

Learn More »

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).

Phase

0.0 miles

Learn More »

Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis

Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a dysimmune condition, cutaneous and visceral fibrosis. Interstitial lung disease (ILD) affects 75% of SSc patients and is the leading cause of death in SSc. No diagnostic or prognostic biomarkers of SSc-associated ILD have been validated to date. The ...

Phase N/A

0.0 miles

Learn More »

CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients

Secondary, exploratory objectives include: To describe clinical improvement category sub-groups (e.g. non-responders versus strong responders) in terms of: target concomitant medication usage, symptomology, quality of life (questionnaires), exacerbation rates (and other adverse events) and lung function parameters, differential blood counts, serum club cell secretory protein (CCSP) levels, other quantitative thoracic ...

Phase N/A

0.0 miles

Learn More »

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group. PREVENE (PREemptive VENEtoclax) trial.

Phase

0.0 miles

Learn More »

Circulating microRNAs and Degenerative Abdominal Aorta Aneurysm

Abdominal aortic aneurysm (AAA) is an aortic dilatation superior or equal to 30 mm with an estimated prevalence at 8% in men over 65 year-old. It evolves with no clinical signal until the rupture of the aortic wall with dramatic outcomes. The pathophysiological mechanisms include extracellular matrix remodeling, smooth muscle ...

Phase N/A

1.39 miles

Learn More »

Therapeutic Education for Harm Reduction in Patients With Alcohol Use Disorder

Alcohol is the most harmful psychoactive substance in terms of overall damage. Though abstinence remains the objective of most pharmacological and non-pharmacological approaches addressing alcohol use disorder, new therapeutic objectives of reduced alcohol intake and controlled-drinking have emerged. A standardized 10 weeks long, the "ChoiziTaConso" (CTC) therapeutic education program consisting ...

Phase N/A

4.59 miles

Learn More »